For researchers and students at the University of Oslo, researchers at Oslo University Hospital (OUS) and Akershus University Hospital (Ahus), members of Oslo Cancer Cluster, Oslo Cancer Cluster Incubator, The Life Science Cluster, Health2B, Norway Health Tech, LMI, Aleap, ShareLab, the Oslo Science Park community and Oslo Science City partners. Free of charge, but you had to sign up.
Registration opens at 4:30 PM, programme starts at 5:00 PM
Programme
Inspirational talks
The rocky road of biotech commercialization
Erik Skullerud, M.Sc., Founder and CEO, Insider Group
Investor perspective on the “rocky road” for biotechs
Ester Sklarsky, M.Sc., Principal, Sound Bioventures
More about the speakers and their talks
Erik has 30 years experience from pharma and biotech (Amgen, Bayer, Nordic Nanovector) within oncology, hematology, nephrology, cardiology, diabetes and bone disease. He was an integral part of building Amgen from a small biotech company to one of the largest in Europe. In his talk he will give glimpses of his career and share lessons learned along the way with regards to biotech commercialization – that can be a rocky road – and tell the background for establishing Insider Group and its role in innovation ecosystem and how the company interacts with other actors.
Ester holds a B.Sc. in Biomedicine and a M.Sc.in Bioentrepreneurship from Karolinska Institutet. She is based in Stockholm. She has worked within life science venture capital investing at Industrifonden and has prior experience as a management consultant from Sirona Health Solutions,
Ester will talk about how she became a venture capitalist (VC), a VC's role in life science innovation and the role of VC's for funding, shaping and challenging companies.
Role model talk
Richard Crispin, PhD, CMC Development Manager, ARTBIO
More about the speaker, his talk and ARTBIO
Richard has a background in chemistry and biomedical sciences, with experience in drug discovery, drug development, cell pharmacology and organic chemistry. He has a PhD in cancer research from The University of Edinburgh.
Now he is a Chemistry Manufacturing and Controls (CMC) Manager i ARTBIO. He will talk about is career path with experience from both academia and industry.
ARTBIO works on Radioligand therapy (RLT). According to their website this is a promising new approach for cancer treatment: "While beta radioligand therapies are currently more common in clinical practice, alpha radioligand therapies offer potentially significantly better efficacy and safety to patients". ARTBIO works on understanding both cancer biology, and the infrastructure needed to effectively design, manufacture, and distribute their therapies.
Meet the companies: radiopharmaceuticals and beyond
Nucleate Norway
AstraZeneca
Networking with companies
Food and beverages, and mingling
About the innovation hangouts
This is an informal meeting place where students and researchers from the University of Oslo (UiO) can interact with actors from the public sector, hospitals, companies, mentors, business clusters and incubators within UiO's innovation ecosystem. We will provide inspirational talks, talks from role models, matchmaking, food and beverages, and mingling.
The overall goal of the UiO Growth House is to strengthen the innovation culture at UiO to put more knowledge from research to use. With this meeting place, we want to inspire researchers and students, give them self-confidence and knowledge about the innovation process, help them build networks, and facilitate collaboration between academia and industry.
The UiO Growth House established the innovation hangouts in collaboration with clusters in 2022. The events are arranged quarterly in the afternoon/evening.
Questions?
Please contact the UiO Growth House, Norunn K. Torheim, Head of communications and public and external relations, at norunnt@uio.no